Microsoft Word[removed]PADAC FDA errata[removed]doc

First Page		Document Content
Design of experiments Evaluation methods Pharmacology Medical statistics Scientific method Placebo-controlled study Clinical trial Ivacaftor Interim analysis Science Research Clinical research		Microsoft Word[removed]PADAC FDA errata[removed]doc Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 110,81 KB Share Document on Facebook

	OPEN SUBJECT AREAS: FLUORESCENCE IMAGING DRUG DEVELOPMENT HIGH-THROUGHPUT SCREENING DocID: 1pyUW - View Document
	Pulmonary-Allergy Drugs Advisory Committee Meeting Lumacaftor/Ivacaftor Tablets for oral use NDAFDA Opening Remarks and Regulatory History DocID: 1eMZq - View Document
	FDA Advisory Committee Briefing Materials ORKAMBI™ (Lumacaftor/Ivacaftor) for CF Page 1 of 98 Sponsor Briefing Document DocID: 1dX4Q - View Document
	11. On page 120, the 3rd sentence in Section 2.5 should read “In my opinion, it would be a bad idea to conclude that ivacaftor was similar to placebo and even worse to conclude that LUM/IVA was better than placebo iv DocID: 1aHHB - View Document
	PDF Document DocID: 17l0S - View Document